BTL expands EXOMIND brain stimulation to OCD, adolescents

The expansion matters because it opens EXOMIND to more patients and addresses a different clinical problem. OCD affects a substantial portion of people worldwide, and the clearance gives practices a new tool for patients whose condition hasn't responded to or who can't tolerate existing treatments. Adolescents struggle with depression—antidepressants either fail or cause side effects that make it harder to sustain care.

Dennis Weimer, MD, a psychiatrist triple board-certified in psychiatry, consultation-liaison psychiatry, and addiction medicine, said in the announcement that EXOMIND has worked well for his depression patients and that the OCD clearance gives him another option. He noted that three-minute sessions make it easier to fit into patients' schedules. Michelle Dees, MD, a board-certified psychiatrist, emphasized that adolescent depression disrupts school, friendships, and family life, and that the adolescent clearance offers clinicians an alternative when antidepressants haven't worked or cause intolerable side effects.

BTL also introduced two operational changes. The platform now offers an intermittent theta burst protocol with sessions as short as three minutes, reducing the time patients must commit to MDD care. The company also launched a new EXOMIND Dual Applicator, which expands how providers can target brain regions and personalize care.

Rohit Mishra, Vice President of Product Strategy & Business Development at BTL, said the company is committed to expanding EXOMIND's capabilities and access to care across age groups and conditions. He stated that EXOMIND is a core part of BTL's portfolio and that the company will continue to invest in its future.

The three-minute theta burst protocol represents a significant shift in how treatment works logistically. For practices managing patient flow and scheduling, shorter sessions mean providers can structure the day with greater adaptability. A patient can receive care in the time it takes to complete intake paperwork at many offices. This matters for keeping patients engaged—they're more likely to complete a course of care when each session fits easily into their schedule.

The Dual Applicator expands the platform's technical reach. By offering providers greater ability to personalize patient care, BTL is positioning EXOMIND as a tool that can adapt to individual patient anatomy and clinical needs rather than a one-size-fits-all device.

BTL is hosting North American EXOMIND Days on October 13–15, 2026, where practices and communities will share experiences and discuss the platform's expanded uses. This event signals the company's intent to build a practitioner community around the device and to educate the market on the new indications.

The company, founded in 1993, operates across dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, and primary care. Its portfolio includes EMSCULPT NEO, EMFACE, EXION, and EMSELLA alongside EXOMIND. BTL holds more than 200 patents and employs over 600 in-house engineers. The breadth of BTL's device portfolio means that practices already using other BTL systems may find EXOMIND a natural addition to their offerings, particularly those in psychiatry or mental health settings.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.